We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.09 | 1.44% | 76.97 | 76.50 | 77.60 | 76.80 | 75.96 | 76.34 | 4,911,684 | 01:00:00 |
From May 2019 to May 2024
By Peter Loftus
U.S. health authorities recommended a pause in the use of Johnson & Johnson's Covid-19 vaccine in order to investigate rare but severe cases of blood clots.
The U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention announced the move Tuesday, after finding that six women between the ages of 18 and 48 years who got the vaccine had developed blood clots.
A panel of outside experts will meet Wednesday to review the matter for the CDC, while the FDA will also conduct an investigation.
J&J's vaccine was the third authorized for use in the U.S. It uses the same technology as a vaccine from AstraZeneca PLC and the University of Oxford, not yet authorized in the U.S. that has also been linked to rare cases of blood clots.
Write to Peter Loftus at peter.loftus@wsj.com
(END) Dow Jones Newswires
April 13, 2021 07:56 ET (11:56 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
